Skip to main content
S&P 5007,522.87-0.92%DOW52,214.71-0.16%NASDAQ24,959.33-1.60%BTC$68,153.00-4.52%ETH$1,916.44-4.15%GOLD$3,880.80-0.12%OIL$89.12+0.43%
Smart Investors Daily
SID Premium
AN

NASDAQ · ANTX

AN2 Therapeutics, Inc.

Healthcare · Biotechnology

$4.44

Down-$0.14 (-3.15%)

Updated Nov 13, 2026, 3:49 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
30.14M
P/E ratio
-0.98
Dividend yield
0.00%
52-week range
$1.00 – $7.19
Volume
186.34K
Avg. volume
90.8K

Price performance · ANTX

ANTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 12, 2026

ANTX closed at $4.44 after 21 trading sessions, up 23.33% for the selected period.

Last close
$4.44
Period change
+23.33%
Period low
$3.37
Period high
$4.69
Daily close
View OHLC price history
ANTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 12, 2026$4.48$4.75$4.34$4.44186.34K
Nov 11, 2026$4.40$4.747$4.2768$4.46197.63K
Nov 10, 2026$3.99$4.505$3.93$4.33271.6K
Nov 9, 2026$4.06$4.13$3.97$4.00496.68K
Nov 6, 2026$3.99$4.11$3.90$4.00240.36K
Nov 5, 2026$4.22$4.255$3.82$3.955152.97K
Nov 4, 2026$4.22$4.31$4.10$4.25131.83K
Nov 3, 2026$4.38$4.55$4.10$4.18160.4K
Nov 2, 2026$4.54$4.64$4.2411$4.35299.61K
Oct 30, 2026$4.66$4.76$4.31$4.53284.72K
Oct 29, 2026$4.57$4.90$4.53$4.69555.79K
Oct 28, 2026$3.86$4.60$3.85$4.52545.42K
Oct 27, 2026$3.61$3.89$3.54$3.86239.63K
Oct 26, 2026$3.55$3.70$3.50$3.63196.18K
Oct 23, 2026$3.61$3.6599$3.47$3.55124.44K
Oct 22, 2026$3.57$3.72$3.521$3.6495.19K
Oct 21, 2026$3.58$3.78$3.57$3.60177.37K
Oct 20, 2026$3.38$3.59$3.36$3.56129.74K
Oct 19, 2026$3.39$3.46$3.21$3.37330.87K
Oct 16, 2026$3.60$3.62$3.30$3.38281.73K
Oct 15, 2026$3.50$3.69$3.50$3.60295.94K

Latest ANTX news

The latest Smart Investors Daily articles mentioning ANTX.

Stock researchCompany · Overview

ANTX research

Overview

Company profile and research snapshot.

Company profile

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.75
Implied upside
—
Analysts
—
ANTX recent ratings
DateFirmRatingTarget
Jul 20, 2026GuggenheimBuy—
May 14, 2026Leerink PartnersOutperform—
May 5, 2025JMP SecuritiesMarket Outperform—
Mar 26, 2025Citizens Capital MarketsMarket Outperform—
Feb 25, 2025Citizens Capital MarketsMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London

MENLO PARK, Calif., November 04, 2026--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 9:30 am GMT and members of management will be available for 1x1 meetings.

Yahoo · Nov 2, 2026

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

MENLO PARK, Calif., November 02, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for epetraborole in polycythemia vera (PV). The Company has now received regulatory clearance in all planned jurisdictions (

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By